Sati Pharma Ltd, an associate concern of Tayobi International (Hong Kong) Ltd., has announced the launch of its operations in India. The new company focus on anti-AIDS and anti-Cancer segments and would offer drugs at competitive prices.

Tayobi International is one of the major manufacturers of bulk steroids and hormones in China.

Addressing a press conference here on October 4, 2003, Prem R Aildasani informed that the company would initially come out with specialty drugs for gynecology, pediatrics, orthopedics and diabetics to be manufactured at the state-of-the-art manufacturing facility that has come up in Mumbai.

“Sati Pharma will concentrate on pharmaceutical formulations, and the R&D department of the parent company is already on the job with the target of formulating affordable drugs for those afflicted with dreaded diseases like Cancer and AIDS”, he said.

Sati’s mission is to bring medicines of international standards, through R&D in both generic as well as patent and proprietary preparations, within the reach of every individual, he explained.

Tayobi International is a HK $ 15 million company with a growth rate of around 40 percent last year. It was set up at Zhejiang in 1992. The company has network offices in New York, London, Dubai, Hong Kong and Shanghai.